GMED · PEAD ↓ 80

Globus Medical reported Q3 2026 EPS of $1.23 on 2026-11-05 (after market close), beating the $1.20 consensus by $0.03 (+2.5%).

Print-day reaction was -6.5% versus the prior close, a sharp reversal despite the modest EPS beat, suggesting the market found fault elsewhere in the report. The overnight gap to the T+1 open compounded the damage, adding another -9.0% to the drawdown — a decisive post-hours fade with no stabilisation. Over the subsequent two trading days the stock drifted +5.9%, a partial recovery that failed to reclaim the losses. Cumulative abnormal return of -11.4% versus SPY.US lands this squarely in PEAD short territory; the drift confirms and extends the initial negative reaction, with the read held through 2027-02-02.